Iggy Get Out was set up to look at Bertha (Motor Neuron Disease) from as many different angles as possible. There are some important observations in this complex condition:

This is a multifactorial disease with a numerous ‘moving parts’.

It is non-cell autonomous.

In sporadic presentations, it’s not a single gene specific issue, it is a network issue.

There is most probably an autoimmune component.

There is most certainly a protein aggregate component in addition to some endogenous viral element.

The 3 M’s (Mitochondria, Microglia and Microtubules) play a critical role.

There are currently no drugs to cure this condition.

The genome carries information to look into the aforementioned.

The Genome:

We are living in an era where we can now sequence the whole human genome (>3 billion base pairs) in quick time. The disease programming takes place in the genome, therefore, the genome carries vital information about a disease that we can’t see from the outside, and can guide us not only in understanding the disease, but also in defining future treatments, diagnostic and prognostic modalities.

We are currently studying Bertha (Motor Neuron Disease) at the genomic and sub-genomic levels. Most studies have overlooked association between gene expression and its regulation, which we envisage conducting in order to understand the role of genes that are impaired in Bertha and their master regulators- the small molecules called micro-RNAs. With this knowledge, we plan to design inhibitors to normalise gene function, create novel therapeutic modalities based on micro-RNA targeting, and provide possible curative strategies. This novel approach can guide us in designing precision or tailored treatments that can be individualized to patient’s need. 

We see the biggest chances of success because of the holistic and in-depth nature of our approach. 

Complete mapping of the whole genomes and their regulators will provide a clear genomic and sub-genomic understanding of the pathways that impinge on Bertha, and guide us to actual targets that can be exploited in developing treatments. Furthermore, a detailed comparison against myriad of databases will provide additional correlations that are necessary in defining treatments that are global in nature, and have the potential to provide benefit to the community at large.  

The uniqueness of our genome work lies in a unidirectional focus and determination in providing design and development of new generation of genome-based therapies, biomarkers for the treatment, diagnosis, and prognosis, in addition to providing a profound understanding of this disease.

MicroRNA:

Iggy Get Out is especially focussed on MicroRNA and their importance in therapeutic development. 

Our research will uncover new and specific MicroRNA candidates that are involved in controlling gene expression, which we will use in targeting specific miRNAs and modulate or block the gene expression that maybe causing certain components of the disease. 

We have access to numerous large set databases and will be compiling highly detailed analysis across all of these in relation to our sequencing.

Specialist Precision Laboratory:

Our main goal is to get a special laboratory up and running as quickly as possible. This lab will be a state-of-the-art facility designed to address any and every issue we encounter in addressing vital questions. We aim to create new biomarkers to measure Bertha and its associated therapies as well as measure tailor made therapies. As this is for the people, by the people, to the people, our aim is that everyone will be able to benefit from the expertise and precision analysis the lab will provide.